证券代码：301263 证券简称：泰恩康 公告编号：2025-082 一、申请注册药品的基本情况 受理号：CYHS2400454 药品名称：非那雄胺他达拉非胶囊 剂型：胶囊剂 规格：每粒含非那雄胺 5mg 与他达拉非 5mg 注册分类：化学药品 3 类 广东泰恩康医药股份有限公司 关于全资子公司收到非那雄胺他达拉非胶囊 药品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司山东华铂 凯盛生物科技有限公司（以下简称"华铂凯盛"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）签发的非那雄胺他达拉非胶囊《药品注册证 书》。现将相关情况公告如下： 非则可直接缓解 BPH 相关的下尿路症状，同时因他达拉非具备改善勃起功能的 作用，还能针对性治疗和消除非那雄胺用药可能引发的勃起功能障碍不良反应。 相比于单一药物治疗，该复方制剂的临床优势显著：每日仅需服用一粒， 起效时间快，不仅能进一步减少药物副作用，还能显著提高患者满意度和治疗 依从性；此外，他达拉非还具有改善血管内皮功能的功效，长期小剂量服用 ...

2024年1至12月份，泰恩康的营业收入构成为：医药代理占比61.1%，医药制造占比37.28%，医药技术 服务占比1.51%，其他业务占比0.12%。 每经AI快讯，泰恩康（SZ 301263，收盘价：27.72元）12月19日晚间发布公告称，公司于近日收到公司 控股股东、实际控制人孙伟文女士的通知，获悉其所持有的公司部分股份办理了解除质押的手续，本次 解除质押240万股。截至本公告日，郑汉杰累计质押股数为3550万股，占其所持股份比例为40.17%。孙 伟文累计质押股数为550万股，占其所持股份比例为8.31%。 截至发稿，泰恩康市值为118亿元。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 王晓波） ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于近日收到公司控股股东、 实际控制人孙伟文女士的通知，获悉其所持有的公司部分股份办理了解除质押的 手续，具体情况如下： | | 是否为控股股 东或第一大股 | 本次解除 | 占其所 持股份 | 占公司总 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 质押数量 | | 股本比例 | 质押 | 质押 | 质权人 | | 名称 | 东及其一致行 | （股） | 比例 | （%） | 起始日 | 解除日 | | | | 动人 | | （%） | | | | | | 孙伟文 | 是 | 2,400,000 | 3.62 | 0.56 | 2024-12-09 | 2025-12-18 | 渤海国际 信托股份 | | | | | | | | | 有限公司 | | 合计 | - | 2,400,000 | 3.62 | 0.56 | - | - | - | 一、股东部分股份解除质押的基本情况 二 ...

Group 1 - The global macroeconomic environment has gradually improved since 2025, leading to a steady upward trend in the A-share market, with major indices like the CSI 300 and ChiNext Index rising over 20% [2] - The technology, consumer, and new energy sectors have been the main drivers of this market rally, with daily trading volume increasing by approximately 15% compared to the same period last year [2] - Equity funds have benefited from asset value growth and optimized investment strategies, with average returns for equity mixed funds exceeding 25% this year, and some thematic funds, such as those focused on artificial intelligence and high-end manufacturing, seeing gains over 40% [2] Group 2 - The Dachen Yuexiang Life Mixed A fund, managed by Qi Weizhong, has underperformed despite the bullish market, with a return of -12.18% since its inception on December 10, 2021 [5] - The fund's heavy allocation to traditional consumer sectors like liquor and duty-free has not performed well, as these sectors face demand ceilings, while emerging consumption areas have not been adequately represented in the portfolio [5] - The fund's performance has been negatively impacted by the weakening competitive edge of some leading companies in its holdings, while new consumer brands have rapidly gained market share [5] Group 3 - The Dachen Consumption Selected Stock A fund has also struggled, with a return of -18.82% since its inception on May 24, 2021, and a year-to-date return of 16.55% [18] - The fund has seen a consistent decline in its asset size, with net assets decreasing to 2.69 billion yuan by September 30, 2025, due to ongoing redemptions [30] - The fund's investment strategy has been criticized for not adapting to the significant changes in the consumer industry, necessitating a reassessment of its thematic focus and investment approach [5][30]

Group 1 - The core point of the article is that Tianen Kang (301263) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Methimazole tablets from the National Medical Products Administration [1] Group 2 - The drug registration certificate signifies regulatory approval for the production and sale of Methimazole tablets, which may enhance the company's product portfolio and market presence [1] - This development could potentially lead to increased revenue streams for the company as it expands its offerings in the pharmaceutical sector [1] - The approval reflects the company's commitment to compliance with national regulations and its capability in the biotechnology field [1]

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate from the National Medical Products Administration for Methimazole tablets, a commonly used medication for hyperthyroidism treatment [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has recently obtained the registration certificate for Methimazole tablets [1] - Methimazole tablets are primarily used to treat hyperthyroidism, particularly in patients with mild symptoms and those with mild to moderate thyroid enlargement [1] Group 2: Product Applications - The medication is also indicated for preventing recurrence in patients post-thyroid surgery [1] - Additionally, Methimazole tablets are utilized as a preparatory medication for patients undergoing radioactive iodine treatment to prevent thyroid storm [1]

Core Viewpoint - The company, TianKang (301263.SZ), has received a notice of acceptance for the production registration application of Indobufen Tablets from the National Medical Products Administration (NMPA) of China, indicating progress in its drug approval process [1]. Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1]. - The NMPA has reviewed the application according to Article 32 of the Administrative Licensing Law of the People's Republic of China and has decided to accept the application [1]. Group 2: Product Information - Indobufen Tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce thrombotic risks [1]. - The drug is intended for use in ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis formation, and it can also be used to prevent thrombosis during hemodialysis [1].

Core Viewpoint - The announcement highlights significant regulatory approvals for two pharmaceutical products from the company's subsidiaries, indicating progress in their product development pipeline and potential market expansion [1] Group 1: Regulatory Approvals - The company's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received a drug registration certificate for Methimazole tablets from the National Medical Products Administration [1] - Another subsidiary, Anhui Tianenkang Pharmaceutical Co., Ltd., received an acceptance notice for the domestic production drug registration application for Indobufen tablets from the National Medical Products Administration [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Anhui Taienkang Pharmaceutical Co., Ltd., has received a notice of acceptance for the production registration application of Indobufen tablets from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Indobufen tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce thrombotic risk [1] - The medication is indicated for ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - Indobufen tablets can also be used to prevent thrombosis during hemodialysis [1]